Establishing SPMS diagnosis can be challenging to neurologists because at least six months of progression must be observed before RRMS can be considered secondary progressive. The worsening of symptoms could be due to a relapse that caused permanent but stable damage after an inflammatory attack ended. In that case, the patient is still in the RRMS phase — or there was a worsening of the condition without inflammatory relapses. Repeat brain MRI scans and a neurologic examination can help determine if the disease has actually progressed to SPMS.
SPMS can be characterized as not active, active (with relapses or evidence of new brain MRI lesions), without progression, or with progression (when there is evidence of worsening of the disease over time, with or without relapses).
People diagnosed with SPMS who are on disease-modifying therapies for MS can often continue taking them. The medications include:
Dimethyl fumarate (Tecfidera)
One FDA approved chemotherapeutic agent, Novantrone (mitoxantrone) made specifically for SPMS (and for worsening relapsing MS), suppresses the immune system. While there is significant unmet need for SPMS treatments, promising therapies are currently progressing through the research and development pipeline.
There are ways for SPMS patients to help manage the disease. Appropriate exercise and healthy eating habits are important for all people with MS. When relapse or worsening of symptoms occur, physical and occupational therapy can help minimize muscle weakness and help restore movement.
Note: Multiple Sclerosis News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis, or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.